Skip to content

The Effects of Fospropofol Disodium, Ciprofol, and Propofol on Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy: A Randomized, Controlled Study

The Effects of Fospropofol Disodium, Ciprofol, and Propofol on Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy: A Randomized, Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115821
Enrollment
Unknown
Registered
2025-12-31
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Interventions

Propofol group:Anesthesia was induced with propofol at 2 mg/kg.
Fospropofol disodium group:Anesthesia was induced with fospropofol disodium at a dose of 10 mg/kg.
Ciprofol group:Anesthesia was induced with ciprofol at a dose of 0.5 mg/kg.

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Female patients aged 18 to 65 years; (2) American Society of Anesthesiologists (ASA) physical status classification I to III; (3) Scheduled for elective laparoscopic cholecystectomy under general anesthesia; (4) Non-smoker (defined as no use of any tobacco products within the past 6 months); (5) Provision of signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with known allergy or contraindications to propofol, fospropofol disodium, ciprofol, or any of their components; (2) History of severe hepatic, renal, pulmonary, or cardiac disease; (3) Pregnant or lactating women; (4) History of chronic nausea and vomiting; (5) History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery; (6) History of nausea and vomiting or use of antiemetic medications within 24 hours prior to surgery; (7) Patients deemed by the investigator to be unsuitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
The overall incidence of PONV in the PACU during the postoperative period;

Secondary

MeasureTime frame
The number of episodes of nausea and vomiting in the PACU postoperatively, along with the frequency and dosage of rescue antiemetic medications administered.;Severity of postoperative nausea and vomiting in the PACU;Number of episodes and incidence of nausea or vomiting within 24 hours after surgery;Adverse reactions during induction, duration of surgery, time to awakening, extubation time, and length of stay in the PACU;Blood concentrations of propofol/ciprofol at the end of surgery, 30 minutes after entering the PACU, and upon discharge from the PACU;Incidence of intraoperative hypotension and bradycardia;

Countries

China

Contacts

Public ContactXiaoqiang Li

West China Hospital of Sichuan University

39006900@qq.com+86 28 8555 3329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026